BSSM updated guideline on management of Erectile Dysfunction

British Society for Sexual Medicine, BSSM has released its guidelines on the management of erectile dysfunction in men. This is an update of the 2008 British Society for Sexual Medicine (BSSM) guidelines. The guidelines have appeared in The Journal of Sexual Medicine.

Erectile dysfunction (ED) has been defined as the persistent inability to attain and/or maintain an erection sufficient for sexual performance. It may be associated with other causes of CVD such as hypertension, dyslipidaemia and endothelial dysfunction.

Key Recommendations -Various recommendations for diagnosis and management are hereunder-

Diagnosis-The diagnosis is based on detailed history, Physical examination and routine and specialized investigations.

• Sexual history—a detailed description of the problem, including the duration of symptoms and original precipitants, should be obtained. Concurrent medical, psychiatric and surgical history may also be recorded.


• All patients should have a focused physical examination. A genital examination is recommended, and this is essential if there is a history of:
  
  
  
  • rapid onset of pain
  
  
  • deviation of the penis during tumescence
  
  
  • the symptoms of hypogonadism
  
  
  • other urological symptoms (past or present)
  
  
  
  


• A digital rectal examination (DRE) of the prostate is not mandatory in ED but should be conducted in the presence of genito-urinary or protracted secondary ejaculatory symptoms


• Blood pressure, heart rate, waist circumference and weight should be measured

Laboratory testing

• The choice of investigations depends on the individual circumstances of the patient. Serum lipids and fasting plasma glucose, and HbA_1C should be measured in all patients


• Hypogonadism is a treatable cause of Erectile dysfunction that may also make men less responsive, or even non-responsive, to phosphodiesterase type 5 inhibitors (PDE5i); therefore, all men with ED should have serum testosterone measured on a blood sample taken in the morning between 08.00 and 11.00


• Serum prostate-specific antigen should be considered if clinically indicated. It should certainly be measured before commencing testosterone and at 3–6 months and then annually after commencing testosterone therapy


• All men with unexplained ED should have a thorough evaluation and any risk factors for CHD that are identified should be addressed. A man with ED and no cardiac symptoms is a cardiac patient until proven otherwise


• The current NICE guidance recommends that all men with type 2 diabetes be asked annually about ED, assessed, and offered oral treatment with the medication with the lowest acquisition cost


• Most patients do not need further investigations unless specifically indicated. However, some patients wish to know the etiology of their Erectile dysfunction and should be investigated appropriately. Other indications for specialist investigations include:
  
  
  
  • young patients who have always had difficulty in obtaining and/or sustaining an erection
  
  
  • patients with a history of trauma
  
  
  • where an abnormality of the testes or penis is found on examination
  
  
  • patients unresponsive to medical therapies that may desire surgical treatment for ED
  
  
  
  


• Surgical problems that cause erectile dysfunction, for example, phimosis, tight frenulum and penile curvatures, should be diagnosed clinically and are usually simple to treat surgically, which results in a permanent cure of Erectile dysfunction.

Treatment

• The primary goal of management of ED is to enable the individual or couple to enjoy a satisfactory sexual experience. This involves:
  
  
  
  • identifying and treating any curable causes of ED
  
  
  • initiating lifestyle change and risk factor modification
  
  
  • providing education and counselling to patients and their partners
  
  
  
  


• Where a potentially curable cause for ED is found, it should be treated in conjunction with ED-specific therapy

Reversible causes of Erectile dysfunction

• Hormonal:
  
  
  
  • hypogonadism
  
  
  • hyperthyroidism/hypothyroidism
  
  
  • hyperprolactinaemia
  
  
  
  


• Post-traumatic arteriogenic ED in young patients


• Drug-induced ED—drugs may affect sexual response in a number of ways:
  
  
  
  • drugs that cause sedation may affect sexual motivation and, indirectly, cause ED
  
  
  • drugs that affect cardiovascular function, such as antihypertensive agents, may act centrally and may also affect penile haemodynamics
  
  
  • some drugs affect endocrine parameters—anti-androgens and oestrogens may affect both sexual desire and erection
  
  
  • drugs that cause hyperprolactinaemia, such as phenothiazines, may also affect sexual desire and erection
  
  
  
  


• Partner sexual problems


• Psychosexual counselling and therapy


• Radical prostatectomy

Lifestyle management

• Lifestyle modifications can greatly reduce the risk of ED, and should accompany any specific pharmacotherapy or psychological therapy. However, pharmacotherapy should not be withheld on the basis that lifestyle changes have not been made


• Lifestyle factors include:
  
  
  
  • psychosocial issues
  
  
  • adverse side effects of non-prescription drugs
  
  
  • influence of any co-morbidities, including those in the partner
  
  
  
  


• The potential advantages of lifestyle changes may be particularly pronounced in those with psychogenic ED, but not in men with severe cardiovascular disease or diabetes

Hypogonadism and testosterone replacement therapy

• The cause of hypogonadism should always be sought before treatment with testosterone is initiated, but this does not mean that treatment for ED should be deferred. Prior assessment and safety monitoring should be performed according to contemporary authoritative guidelines


• Men with a total serum testosterone that is consistently <12 nmol/l might benefit from a 3 month trial of testosterone replacement therapy for ED and should be managed according to current guidelines (see algorithm below)


• A range of well-tolerated testosterone formulations is available including
  
  
  
  • oral
  
  
  • transdermal gel
  
  
  • transdermal axillary solution
  
  
  • long-acting injection 1000 mg/4 ml deep intra-muscular injection (3 monthly)
  
  
  • traditional depot injection 100/250 mg (2–3 weekly)
  
  
  • implanted pellets
  
  
  
  

First-line treatment

• Phosphodiesterase 5 inhibitors,PDE5Is (e.g. avanafil, sildenafil, tadalafil, vardenafil):
  
  
  
  • have proven efficacy and safety both in non-selected populations of men with ED and in specific sub-groups of patients (for example, men with diabetes and those who have had a prostatectomy)
  
  
  • avanafil, sildenafil, and vardenafil are relatively short-acting drugs, having a half life of approximately 4 hours, whereas tadalafil has a significantly longer half life of 17.5 hours
  
  
  • are not initiators of erection but require sexual stimulation in order to facilitate an erection. It is currently recommended that patients should receive eight doses of a PDE5 inhibitor with sexual stimulation at maximum dose before classifying a patient as a non-responder
  
  
  • for men with ED and bothersome LUTS, daily tadalafil should be considered as first-line therapy
  
  
  • inadequate prescribing or instruction is the major cause of PDE5I failure:
    
    
    
    • daily or frequent dosing regimens frequently salvage men who have failed with on-demand therapy
    
    
    • correction of testosterone levels below 10.4 nmol/l may salvage non-responders to PDE5Is
    
    
    • salvaging patients from failure with PDE5Is is a cost-effective strategy
    
    
    
    
  
  
  
  


• Vacuum erection devices:
  
  
  
  • are highly effective in inducing erections regardless of the aetiology of the ED
  
  
  • they may be useful combined with PDE5Is and injection therapy post-radical prostatectomy and to salvage treatment failures
  
  
  • combined with variable sized insert tubes can be helpful in correcting penile curvature
  
  
  • reported satisfaction rates vary considerably from 35% to 84%
  
  
  • long-term usage of vacuum devices also varies but is considerably higher than for self-injection therapy
  
  
  • most men who are satisfied with vacuum devices continue to use them long term
  
  
  • adverse effects include bruising, local pain, and failure to ejaculate. Partners sometimes report the penis feels cold
  
  
  • serious adverse events are very rare but skin necrosis has been reported
  
  
  
  

Second-line treatment

• Intracavernous injection therapy (e.g. Caverject, Viridal)


• Intraurethral alprostadil (e.g. MUSE)


• Topical alprostadil (e.g. Vitaros)

Third-line treatment

• Penile prosthesis:
  
  
  
  • should be offered to all patients who are unwilling to consider, failing to respond to, or unable to continue with medical therapy or external devices. All patients and their partners should be counselled pre-operatively, see and handle all the available devices and, if possible, speak to other patients who have had surgery
  
  
  • particularly suitable for those with severe organic ED, especially if the cause is Peyronie's disease or post priapism. All patients should be given a choice of either a malleable or inflatable prosthesis
  
  
  
  

In the end, the role of Patient/partner education cannot be undermined as an understanding by the patient and partner of basic anatomy and physiology and the purpose of blood and specialist investigations is helpful.Moreover, provision of educational information is valuable reinforcement for patients.

For further reference log on to :